Citadel Advisors
NERV icon

Citadel Advisors’s Minerva Neurosciences NERV Stock Holding History

Citadel Advisors’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,663
Closed -$38K – 13683
2022
Q1 		$38K Sell
5,663
-3,212
-36% -$19.7K ﹤0.01% 12968
2021
Q4 		$57K Sell
8,875
-18,250
-67% -$172K ﹤0.01% 13178
2021
Q3 		$378K Buy
27,125
+1,862
+7% +$28K ﹤0.01% 10550
2021
Q2 		$469K Buy
25,263
+7,688
+44% +$165K ﹤0.01% 10188
2021
Q1 		$411K Buy
+17,575
New +$439K ﹤0.01% 10115
2020
Q4 		– Sell
-4,838
Closed -$123K – 11303
2020
Q3 		$123K Buy
4,838
+813
+20% +$22K ﹤0.01% 9145
2020
Q2 		$116K Sell
4,025
-238
-6% -$14K ﹤0.01% 8910
2020
Q1 		$205K Buy
+4,263
New +$257K ﹤0.01% 7975

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's NERV Position: Q2 2025 in Review

Citadel Advisors sold out of Minerva Neurosciences (NERV) in Q2 2025, closing a stake of 12,915 shares — an estimated $22K sold.

Citadel Advisors first reported a position in NERV in Q1 2017 and held it in 20 quarters. The position peaked at $1.01M in Q3 2018. 21 funds tracked by Wall St. Rank hold NERV as of Q2 2025.

  • Citadel Advisors reported no remaining Minerva Neurosciences position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 12,915 Minerva Neurosciences shares in Q2 2025, an estimated $22K.
  • Citadel Advisors first reported a position in Minerva Neurosciences in Q1 2017 and held it in 20 quarters.
  • Citadel Advisors's Minerva Neurosciences position peaked at $1.01M in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.